DISTINGUISHED FACULTY
Ubiquitin Drug Discovery and Diagnostics 2009 (ARCHIVE)
Date: October 13, 2009 — October 14, 2009
Location: Park Hyatt at the Bellevue (Philadelphia)
DISTINGUISHED FACULTY DETAILS
Click to Download BrochureDISTINGUISHED FACULTY (Partial List)
Aaron Ciechanover, D.Sc., MD. Nobel Laureate
Dr. Ciechanover is currently Distinguished Research Professor in Ruth and Bruce Rappaport Faculty of Medicine and Research Institute at Technion-Israel Institute of Technology. Together with Avram Hershko and Irwin Rose, Dr. Ciechanover received the Nobel Prize in Chemistry in 2004 for the discovery of ubiquitin-mediated protein degradation. He is also a member of the Israel Academy of Sciences and Humanities, the Pontifical Academy of Sciences and a foreign associate of the United States National Academy of Sciences.
Alfred Goldberg, Ph.D., Professor of Cell Biology, Harvard Medical School
Dr Goldberg is one of the true pioneers of the ubiquitin field, having first described the tagging and degradation of proteins in the 1960s.
Joseph Bolen, PhD., Chief Scientist Officer, Millennium Pharmaceuticals
Dr. Bolen joined Millennium in 1999 as Vice President of Oncology and was promoted to Senior Vice President of Discovery Research in 2002. In this role, he headed all biological research in the areas of oncology, inflammation, metabolic disease and cardiovascular disease as well as all genomics, informatics and platform technologies. In 2003 Dr. Bolen was appointed Senior Vice President of Research and Drug Discovery, a role in which he headed all biological research and related functions as well as all drug discovery functions. Dr. Bolen was appointed Chief Scientific Officer in 2006.
Keith Wilkinson, PhD, Professor of Biochemistry, Emory University School of Medicine
Several of the nearly 100 known Deubiquitylating enzymes (DUBs) have been linked with various diseases, including cancer, neurodegenerative disease, and bacterial infection. Inhibitors and activators of DUBs are being studied and evaluated as potential therapies for these diseases.
Mark Hochstrasser, Ph.D., Professor of Molecular Biophysics and Biochemistry, Yale University
Ubiquitin's cousins - SUMO, ISG15, and others, are becoming increasingly interesting as therapeutic targets, being linked to critical cellular control mechanisms and a number of diseases including cancer and diabetes.
Peter Jackson, PhD, Director, Genentech Inc. San Francisco, CA
Dr. Jackson's lab is specialised in researching on the composition of signaling complexes that control receport signaling from the primary cilium, cell cycle control, and ubiquitin-proteasome pathways. Other than being a Director and Staff Scientist in Genentech, Dr. Jackson is a professor at both Stanford University School of Medicine and Stanford Univeristy Medical Center.
Wafik S El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology, University of Pennsylvania School of Medicine
Molecular medicine is increasingly concerned with pharmacodynamic endpoints for clinical monitoring, as well as diagnostic and prognostic applications. Several components of the ubiquitin (and ubiquitin-like protein) pathways have great promise as biomarkers for these purposes.
Paul Andrews, PhD, Scientist, Amgen Inc. Cambridge, MA
Dr. Andrews is a Scientist in Amgen Inc. in the Lead Discovery Organization and he is specialising in the ubiquitin proteasome pathway.
